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Edited by Vladimir SkulachevAbstract A number of viral and eukaryotic proteins which
undergo a lipophilic modiﬁcation by the enzyme N-myristoyl-
transferase (NMT: NMT1 and NMT2) are required for signal
transduction and regulatory functions. To investigate whether
NMT2 contributes to the pathogenesis of colorectal carcinoma,
we observed a higher expression of NMT2 in most of the cases
of cancerous tissues compared to normal tissues (84.6% of
cases; P < 0.05) by Western blot analysis. Furthermore,
protein–protein interaction of NMTs revealed that m-calpain
interacts with NMT1 while caspase-3 interacts with NMT2.
Our ﬁndings provide the ﬁrst evidence of higher expression
of NMT2 in human colorectal adenocarcinomas and the
interaction of both forms of NMT with various signaling
molecules.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Lipid modiﬁcation; N-myristoyltransferase 2;
m-Calpain; Caspase-3; p53; Bcl21. Introduction
Myristoylation is a co-translational lipid modiﬁcation of
proteins [1] in which myristate (a 14-carbon fatty acid) is
covalently attached to the amino terminus of various cellu-
lar, viral and onco proteins (see Refs. [2–6] for reviews). Cel-
lular myristoylated proteins have diverse biological functions
in signal transduction and oncogenesis [2–6]. The processes
of myristoylation is catalyzed by the ubiquitously distributed
eukaryotic enzyme N-myristoyltransferase (NMT), which is
a member of Glycylpeptide N-tetradecanoyltransferase (EC
2.3.1.97) [2–6]. Recent studies showed that NMT exists in
several distinct forms varying in either apparent molecular
weight and/or subcellular distribution [7–11]. King and Shar-
ma [7] provided the ﬁrst evidence for the existence of multi-
ple forms of bovine brain NMT. Later, McIlhinney et al. [8]Abbreviations: HCCL, human colon cancer cell lines; MetAP, methi-
onine aminopeptidase; NIP71, NMT inhibitor protein 71; NMT1,
myristoyltransferase 1; NMT2, myristoyltransferase 2; PEST, proline
(P), glutamate (E), serine (S), and threonine (T) residues; SDS–PAGE,
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
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doi:10.1016/j.febslet.2006.02.076also identiﬁed two forms of NMT in bovine brain cortex.
Subsequently, Glover and Felsted [9] showed that bovine
brain NMT exists as a heterogenous mixture of NMT sub-
units. The gene for the NMT enzyme is ubiquitous in all
eukaryotes, sharing highly conserved domains across species
as diverse as Saccharomyces cerevisiae and humans [12–14].
Mammals and plants have two genes for NMT, NMT1
and NMT2 while other species like the fruit ﬂy appear to
have only one [10,15–17]. The predicted 496-amin acid hu-
man NMT-1 protein shares 77% and 97% sequence identity
with human NMT2 and mouse NMT1, respectively, indicat-
ing that NMT1 and NMT2 represent two distinct families of
NMT [10]. Two types of NMT, NMT1 and NMT2, were
identiﬁed and cloned from various sources [10,11].
C-Src is overexpressed in a number of human cancers,
especially those of colon [18,19] and breast [20]. The tyrosine
kinase activities of N-myristoylated pp60c-src and pp62c-yes
protein kinases are signiﬁcantly elevated in primary colorectal
adenocarcinoma as well as in their corresponding cell lines
relative to those of normal cells [19–21]. We have reported
that NMT activity is higher in colonic epithelial neoplasms
than in normal appearing colonic tissue and that increased
NMT activity appears at an early stage in colonic carcinogen-
esis [22]. Furthermore, we observed that the NMT expression
is elevated in human colon [23] and gallbladder carcinomas
[24]. Recently, we reported high expressions of both NMT1
and NMT2 in human brain tumors [25]. Protein myristoyla-
tion is a co-translational process that occurs after the re-
moval of methionine. However, there have been reports
documenting post-translational myristoylation of protein
such as the pro-apoptotic protein BH3 interacting domain
[26,27]. Methionine aminopeptidase (MetAP) is the enzyme
responsible for the removal of methionine from the NH2-ter-
minus of newly synthesized proteins [28]. We observed ele-
vated MetAP2 expression for the ﬁrst time in human
colorectal adenocarcinomas and various human colon cell
lines (HCCLs) [29,30]. In addition, we have demonstrated
the diﬀerential expressions of pp60c-src, MetAP2 and NMT1
in HT29, human colon cell line [30]. We discovered and char-
acterized a NMT inhibitor protein 71 (NIP71) [31]. Recently,
we identiﬁed that the NIP71 is homologous to heat shock
cognate protein 70 [32]. Our previous studies have focused
on NMT1 and its expression in various tumors. To our
knowledge, no reports are available related to NMT2 in colo-
rectal adenocarcinomas. In this study we investigated the
expression of NMT2 in human colorectal adenocarcinoma
and HCCLs.blished by Elsevier B.V. All rights reserved.
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family of Ca2+-dependent cysteine protease, are involved in on-
cotic cell death in a variety of models [33]. Recently we reported
that the activity and protein expression ofm-calpain was signif-
icantly higher in colorectal adenocarcinomas than in normal
[34]. Previously, we reported thatm-calpain proteolyzes the hu-
man NMT1 which contains proline (P), glutamate (E), serine
(S), and threonine (T) residues (PEST) regions (proline, glu-
tamic acid, serine, and threonine) and cysteine protease which
recognize these regions [35]. The present report examines pro-
tein-protein interaction of NMT1 and NMT2 with m-calpain
and caspase-3 in human colorectal adenocarcinoma tissues
and HCCLs. Interestingly, we observed NMT1 and NMT2
interact diﬀerently with m-calpain and caspase-3. In addition
we studied the interactions of two forms of NMT with diﬀerent
signaling molecules such as Bcl2 and p53 in human colon tumor
tissues and HT29, a human colon cell line.2. Materials and methods
2.1. Materials
Polyclonal antibody against human NMT1 was produced and puri-
ﬁed as described elsewhere [24]. Anti-NMT2 was obtained from BD
biosciences, Canada. Anti-p53, anti-Bcl2, and anti-caspase-3 were ob-
tained from Santa Cruz Biotechnology Inc. USA. Anti-m-calpain was
obtained from Chemicon International, USA. Anti-b-actin was ob-
tained from Sigma–Aldrich Canada. Nitrocellulose membranes were
purchased from Bio Rad Laboratories, Canada. Benzamidine, phen-
ylmethanesulfonyl ﬂuoride (PMSF), leupeptin, and were obtained
from Sigma–Aldrich Canada. Other reagents were of analytical grade
and were purchased from BDH or Sigma–Aldrich Canada.
2.2. Human colorectal specimens and preparation of tissue extracts
Thirteen colorectal cancer patients were selected for the evaluation
of expression of NMT2. The human colorectal tissues were collected
from the Royal University Hospital, University of Saskatchewan, Sas-
katoon, Saskatchewan, Canada. Surgical pathology specimens from 13
patients who had undergone resection for colorectal adenocarcinoma
were collected directly from the surgical operating room in the fresh
state (before being immersed in tissue ﬁxative). Following gross inspec-
tion, normal and tumor samples were dissected and immediately frozen
at 80 C. Normal-appearing colonic mucosa far removed from the
cancer was similarly dissected and frozen.
All procedures were carried out at 4 C, unless otherwise stated. Tis-
sues were homogenized in 100 mM Tris–HCl, pH 7.4 containing 1 mM
EGTA, 1 mM EDTA, 10 mM 2-mercaptoethanol, 1 mM benzamidine,
0.2 mM PMSF, and 0.5 lg/ml leupeptin. The crude homogenate was
centrifuged for 30 min at 10000 · g and the supernatant was ﬁltered
through glass wool. The supernatant obtained was used for further
analysis.
2.3. Cell culture and cell lysate preparation
The HT29, SW480, SW620, and WiDr HCCLs were obtained from
the American Type Culture Collection (ATCC) and grown in DMEM
and 10% fetal calf serum (Gibco). Colo320, DLD1, HCT15, and
HCT116 HCCLs were also from ATCC and grown in RPMI-1640
media with 10% fetal calf serum. All cells were maintained at 37 C
and 5% CO2. Cells were washed twice in PBS and lysed in ice-cold,
modiﬁed RIPA buﬀer [0.1% sodium dodecyl sulfate (SDS), 1% Non-
idet P-40, 0.1% deoxycholate, 150 mM sodium chloride, 10 mM so-
dium phosphate (pH 7.0), 100 lM sodium vanadate, 50 mM sodium
ﬂuoride, 50 lM leupeptin, 1% aprotinin, 2 mM EDTA, and 1 mM
dithiothreitol] [18]. Lysates were centrifuged at 14000 rpm for 15 min
at 4 C and the supernatant was used for further analysis.
2.4. Immunoprecipitation
Immunoprecipitation was carried out as described previously [36].
Brieﬂy, the total protein (500 lg) obtained from human colorectal nor-
mal and tumor tissue extracts as well as HT29 cell lysate were incu-bated separately for 2–12 h at 4 C with anti-NMT1, anti-NMT2,
anti-m-calpain, anti-caspase3, anti-p53 or anti-Bcl2 antibody. Immu-
nocomplexes were adsorbed to 50 ll of protein A/G-Sepharose beads
and incubated 2 h at 4 C. The immunoadsorbed pellets were washed
in buﬀer 50 mM Tris–HCl, pH 7.5 containing 0.1% (w/v) SDS, 1%
Triton X-100 and 150 mM NaCl and heated at 95 C in 1· reducing
Laemmli loading buﬀer, before loading onto sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS–PAGE). SDS–PAGE
resolved samples were transferred onto nitrocellulose membranes.
Each blot was incubated with its respective antibody at 1:1000, washed
and probed with either anti-rabbit or anti-mouse IgG horseradish per-
oxidase conjugate diluted 1:2000. Membranes were then incubated in
chemiluminescence reagents and exposed to Kodak X-OMAT Blue
XB-1 ﬁlm for detection. Results were analyzed by using image analysis
software (NIH Image).
2.5. SDS–PAGE and Western blot analysis
Total proteins were isolated from human colon normal and cancer
tissues as described above. All HCCLs were lysed directly in a loading
buﬀer containing 65 mM Tris–HCl, pH 7.0, 2.3% (w/v) sodium dodecyl
sulfate (SDS), 5% 2-mercaptoethanol, 10% glycerol, and 0.05% (w/v)
bromophenol blue. Fifty micrograms of total cellular protein was re-
solved on a 10% SDS–PAGE according to the procedure described
by Laemmli [37]. Gel transfer to nitrocellulose membrane and blocking
were performed using standard procedures [38]. The blot was incu-
bated with the NMT2 antibodies at 1:1000, washed and probed with
an anti-mouse IgG horseradish peroxidase conjugate diluted 1:2000.
Membranes were then incubated in chemiluminescence reagents and
exposed to Kodak X-OMAT Blue XB-1 ﬁlm for detection. The blot
was reprobed with b-actin after stripping for 30 min in 62.4 mM
Tris–HCl, pH 6.8 and 2% SDS containing 10 mM b-mercaptoethanol
at 60 C.
2.6. Other methods
Protein concentration was measured by the method of Bradford [39]
using bovine serum albumin as the standard.
2.7. Statistical analysis
All the data are reported as the means ± S.E.M. The diﬀerences be-
tween the mean values were tested for statistical signiﬁcance by the
two-tailed Student’s t test.3. Results
3.1. Expression of NMT2 in human colorectal tissues and
HCCLs
Our previous studies demonstrated the higher expression
of NMT1 in animal model and human colorectal cancer tis-
sues [22,23]. The animal studies suggested that increased in
NMT activity appeared at an early stage in colonic carcino-
genesis [22]. However, the expression of NMT2 in colorectal
carcinoma was not studied. The present study analyzed the
alteration of NMT2 in colorectal mucosa. Equivalent
amounts of protein from 13 cases of human colorectal nor-
mal tissue and adenocarcinomas and two polyps were sub-
jected to immunoblotting and probed with anti-NMT2 as
described in Section 2 (Fig. 1). This resulted in a prominent
overexpressed immunoreactive band of NMT2 with an
apparent molecular mass of 65 kDa in human colorectal tu-
mor tissues (84.6% of cases; P < 0.05; Fig. 1A; lanes, C).
The same 65 kDa band was poorly expressed in samples
from mucosal sections distal to the tumor (Fig. 1A; lanes,
N). The quantitative analysis of 65 kDa immunoreactive
band demonstrated a signiﬁcant increase in NMT2 expres-
sion in colorectal cancer tissues compared to normal mucosa
(Fig. 1B). In addition, we observed a high expression of
NMT2 in polyps (Fig. 1B; lanes, P1,P2).
Fig. 1. Expression of N-myristoyltransferase 2 in human colorectal carcinoma. (A) Western blot analysis of human colorectal polyps (P), normal
(N), and tumor tissue (C) extracts probed with anti-NMT2. Fifty micrograms of proteins was loaded onto each lane of an SDS–PAGE and
immunoblotted with anti-NMT2 as described in Section 2. (B) Quantitation analysis of (A)was carried out using image software (NIH at http://
rsb.info.nih.gov/nih-image/download.html). The data presented are representative of at least three separate experiments. Statistical signiﬁcance was
determined using Student t test analysis; *P < 0.05.
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lon cancer [2–6,19]. Furthermore, we analyzed NMT2 expres-
sion using Western blot analysis in various HCCLs (Colo320,
SW480, SW620, HT29, DLDI, WiDr, HCT15 and HCT116).
We observed the NMT2 protein expression was higher in
Colo320, compared to other cell lines. The expression of
NMT2 in SW480, SW620 and HCT116 were slightly higher
compared to HT29, DLD1 and WiDr. However, the protein
expression of NMT2 in HCT15 was poorly expressed
(Fig. 2). Furthermore, we compared the protein expressions
of c-Src and NMT2 in the above-mentioned cell lines to
identify whether NMT2 is involved in the myristoylation ofFig. 2. Western blot analysis of human colon cell lines lysates probed
with anti-NMT2. Fifty micrograms of proteins was loaded onto each
lane of an SDS–PAGE and immunoblotted with anti-NMT2 as
described in Section 2. The data presented are representative of at least
three separate experiments.pp60c-src. No similarity in protein expressions of c-Src and
NMT2 was observed (data not shown).
3.2. Interaction of NMTI and NMT2 with proteases
Protein–protein interactions are controlled by the availabil-
ity of the component proteins, which are principally controlled
by the net eﬀects of synthesis and degradation of proteins. The
calpain and ubiquitin–proteasome pathways function as the
major proteolytic systems responsible for the regulated degra-
dation of various proteins [33,40]. In our previous study, we
observed the abolishment of NMT activity after in vitro prote-
olysis of cardiac NMT by m-calpain and this indicated that
calpain may regulate NMT expression [34]. Here, we studied
the interaction of both forms of NMT with m-calpain and
caspase-3 in human colorectal normal and adenocarcinoma
tissues and in HT29. Immunoprecipitation was used to
monitor the interaction between NMT1 and m-calpain using
NMT1 antibody. We observed the interaction of NMT1 with
m-calpain in normal, tumor and HT29 samples (Fig. 3A, lanes
1–3). Furthermore, the immunoprecipitation analysis of m-cal-
pain using NMT2 antibody revealed no interaction between
NMT2 and m-calpain (Fig. 3A, lanes 4–6). Our present study
revealed that m-calpain interacts with human NMT1 as part of
Fig. 3. Interaction between NMTs (NMT1 and NMT2) and proteases
(m-calpain and caspase-3). Immunoprecipitations was performed by
using control IgG, anti-NMT1 or a anti-NMT2 on tissue extracts/cell
lysates of human colorectal normal (lanes, 1 and 4); tumor (lanes, 2
and 5); and HT29 (lanes, 3 and 6). Following immunoprecipitation and
SDS–PAGE, Western blot analysis was performed using antibodies
speciﬁc for either m-calpain or caspase-3 as described in Section 2. The
data presented are representative of at least three separate experiments.
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static conditions.
To study the protein–protein interaction of NMTs with cas-
pase-3, we carried out co-immunoprecipitation analysis of cas-
pase-3 with NMT1 and NMT2 antibodies using human
normal, tumor and HT29 samples (Fig. 3B). We observed that
the NMT2 interacts with caspase-3 in normal and cancerous
samples (Fig. 3B, lanes 4–6) whereas, NMT1 was failed to
interact with caspase-3 (Fig. 3B, lanes 1–3). These data suggest
that NMTs may be involved in the calpain/caspase-mediated
pathway during the development of cancer.
3.3. Interaction of NMTs between p53 and Bcl2
Mutations in the p53 gene are among the most common ge-
netic disorders in human cancer, including those of breast, co-
lon, lung and liver origin [41]. Increased expressions of NMT
in p53 mutant cases suggest that wild-type p53 may have a neg-
ative regulatory eﬀect on NMT gene expression [24]. It is crit-
ical to identify the pathways responsible for the activation and
suppression of p53 activity in cancerous cells. In our present
study, immunoprecipitation analysis of p53 with NMT1 and
NMT2 antibodies revealed the interaction of p53 with
NMT1 and NMT2 in human normal, tumor and HT29 sam-
ples (Fig. 4A). Interestingly, interaction of p53 with NMT1
was more intense in human colorectal adenocarcinoma than
in normal mucosa. (Fig. 4A, lanes 1 and 2). Similarly, the
interaction of p53 with NMT1 in HT29 cells was more signif-
icant (Fig. 4A, lane 3 vs. 1). We observed the interaction of p53
with NMT2 in human normal and tumor tissues extracts and
in HT29 (Fig. 4B, lane 4 and 5). While, no change in intensityFig. 4. Interaction of NMTs (NMT1 and NMT2) between p53 and
Bcl2. Immunoprecipitations was performed by using control IgG, anti-
NMT1 or anti-NMT2 on tissue extracts/ cell lysates of human
colorectal normal (lanes, 1 and 4); tumor (lanes, 2 and 5); and HT29
(lanes, 3 and 6). Following immunoprecipitation and SDS–PAGE,
Western blot analysis was performed using antibodies speciﬁc for p53
or Bcl2 as described in Section 2. The data presented are representative
of at least three separate experiments.of interaction between NMT2 and p53 was observed across
normal and cancerous tissues, a slightly higher interaction oc-
curred in HT29 cells. (Fig. 4B, lane 6 vs. 4). These data suggest
that NMTs may be involved in the p53 pathway during cancer
development.
Bcl2 overexpression leading to inhibition of cell death signal-
ing has been observed as a relatively early event in colorectal
cancer development. Several studies of colorectal adenocarci-
nomas have detected expression of Bcl2 protein using immuno-
histochemistry [21,42–47]. We examined the interaction of Bcl2
with NMT1 and NMT2 by immunoprecipitation analysis in
human normal, tumor and HT29 samples (Fig. 4B). In this
experiment, NMT1 failed to interact with Bcl2 in any of the
samples tested (Fig. 4B, lanes 1–3), whereas Bcl2 interacted
with NMT2 (Fig. 4B, lanes 4–6). These data suggest that
Bcl2 prefers to associate with NMT2 but not with NMT1.4. Discussion
Our previous studies on colon cancer showed elevated levels
of activity and expression of NMT in rat and human colonic
tumors as well as in some HCCLs [2,4,22,23]. In these studies,
we were focusing on NMT1 and its regulation in colon carci-
nogenesis. In our present study, we demonstrate for the ﬁrst
time a higher expression of NMT2 in colorectal adenocarci-
noma patients as well as in some HCCLs. These results indi-
cate that the NMT2 gene is upregulated during molecular
events that take place during the malignant formation of colon
tissues. Higher expression of NMT2 was reported in rat hepa-
toma cells by dioxin toxicity and the inducible level of NMT2
was a direct consequence of Ah receptor activation [48].
C-Src is overexpressed in a number of human cancers, espe-
cially those of colon [18,19] and breast [20]. The tyrosine ki-
nase activities of N-myristoylated pp60c-src and pp62c-yes
protein kinases are signiﬁcantly elevated in primary colorectal
adenocarcinoma as well as in their corresponding cell lines rel-
ative to those of normal cells [19–21]. Previously, we suggested
that the increased synthesis of pp60c-src in colon cancer re-
quires increased levels of N-myristoylation in order to facilitate
lipid modiﬁcation for newly synthesized proteins. In the pres-
ent study, we were unable to observe any co-relation between
NMT2 and c-Src level expression in HCCLs. This observation
indicates the possibility that NMT2 may not be involving in
the myristoylation of pp60c-src, but may be involved in the
myristoylation of other proteins in colon adenocarcinomas.
Further studies are needed to distinguish the regulation of
NMT1 and NMT2 on the myristoylation of various proteins
in colon carcinogenesis. The speciﬁc role of each form of
NMT in protein myristoylation has not yet been studied.
Recently, the importance of calpain in the metastatic process
has received great attention. Calpain-mediated proteolysis rep-
resents a major pathway of post-translational modiﬁcation
that inﬂuences various aspects of cell physiology including
apoptosis, cell migration and cell proliferation [49–51]. Cal-
pains cause limited proteolysis of substrates, resulting in the
alteration of the activity of the substrate. PEST sequences
are believed to be the intramolecular signals for rapid proteo-
lytic degradation by m-calpain. Our previous study suggested
that bovine cardiac NMT1 has poor PEST regions and the
elimination of NMT activity by m-calpain proteolysis occurs
in vitro [35]. The present study revealed that m-calpain could
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that both forms of NMT may regulate diﬀerently in cellular
signaling. Cross-talk between calpain and caspase proteolytic
systems has complicated eﬀorts to determine their distinct roles
in apoptotic cell death. It has been observed that calpastatin
overexpression decreased calpain activation, increased cas-
pase-3-like activity, and accelerated the appearance of apopto-
tic nuclear morphology [52]. The involvement of calpains and
caspases in pathological conditions are unclear. Wang et al.
[53] reported that the endogenous calpain inhibitor, calpsasta-
tin, was degraded not by calpains but by caspases during apop-
tosis. In addition, caspase inhibitor could reduce calpastatin
breakdown in cultured cells [53]. It may be possible that cas-
pase 3 might indirectly activate calpain via calpastatin degra-
dation. It is worth noting the diﬀerence in the interaction of
the two forms of NMT with m-calpain and caspase-3.
NMT1 was able to interact with m-calpain, but not with
NMT2, whereas, NMT2 could interact with caspase-3 but
not with m-calpain. It is plausible that a diﬀerential regulation
exists for NMT1 and NMT2 by m-calpain and caspase-3.
Despite the massive amount of knowledge that has accumu-
lated about p53, there is still much to learn about its role in tu-
mor suppression. Tumors with increased expression of NMT
and p53 were associated with poor clinical outcomes as evi-
denced by their mean survival times [24]. This study showed
a strong interaction between NMT1 and p53 in colon cancer
tissues and in HT29. However, the interaction of NMT2 with
p53 was similar in cancerous and normal mucosa. It is critical
to identify the pathways responsible for suppression of apop-
tosis by NMT1 and NMT2 in colon cancer. Bcl-2 suppresses
apoptosis induced by a wide variety of stimuli in multiple cell
types. Our present study shed light on the interaction of two
forms of NMT with Bcl2. The interesting observation was that
Bcl2 interacts with NMT2, whereas this apoptotic factor was
unable to interact with NMT1. Further studies are needed to
explain the role of NMT1 and NMT2 in the regulation of
apoptosis in colon carcinoma.
In conclusion, we have demonstrated the overexpression of
NMT2 in colorectal cancer tissues as well as in HCCLs
employing Western blot analysis. Furthermore, we observed
the interaction of diﬀerent forms of NMT (NMT1 and
NMT2) with diﬀerent cell signalling molecules in colon cancer.
NMT1 and NMT2 interact diﬀerently with m-calpain and cas-
pase-3. Further work will rule out the possibility that myris-
toylation is regulated by m-calpain and caspase-3 using
particular protease inhibitors. Strong protein–protein interac-
tion of NMT1 with p53 was observed in colon cancer tissues
and HT29. Currently we are investigating the speciﬁc role of
NMT1 and NMT2 by RNAi studies on myristoylation of pro-
teins and their involvement in the regulation of apoptosis.
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